

Summary

Order Reference: c-chelo.gable@milliman.com | Report as of: 09-23-2018 12:53 PM | using Currency as USD

DAVITA INC.

Tradestyle(s): -

ACTIVE HEADQUARTERS

Address: 2000 16th St, Denver, CO, 80202, UNITED STATES
Phone: (303) 405-2100
D-U-N-S: 88-307-3371
In Portfolio: No

Failure Score	Delinquency Score	Age of Business	Employees
35	6	24 years 1994 Year Started	70,335 100 (here)

Company Profile

D-U-N-S

88-307-3371

Legal Form

Corporation (US)

History Record

Clear

Date Incorporated

04-03-1994

State of Incorporation

Delaw are

Ownership

Public: DVA (NYS)

Mailing Address

PO Box 2037
Tacoma, WA 98401
United States

Telephone

(303) 405-2100

Website

[www.davitahealthcarepart...](#)

Present Control Succeeded

1994

Annual Sales

US\$ 10,876,634,000

Employees

70,335 (100 here)

Age (Year Started)

24 years (1994)

Named Principal


Kent J Thiry, CHB-CEO

Line of Business

Kidney dialysis centers

Risk Assessment

Overall Business Risk



Maximum Credit Recommendation

US\$ 250,000


The recommended limit is based on a high probability of severe delinquency or business failure. Guarantee Advised.

Dun & Bradstreet Thinks...

- Overall assessment of this organization over the next 12 months: **PAYMENT BEHAVIOR CONCERNS**
- Based on the predicted risk of business discontinuation: **EXHIBITING SOME FINANCIAL DIFFICULTIES**
- Based on the predicted risk of severely delinquent payments: **VERY HIGH POTENTIAL FOR SEVERELY DELINQUENT PAYMENTS**

D&B Viability Rating

Portfolio Comparison Score



Company's risk level is: **MODERATE-HIGH**

Probability that a company will go out of business, become dormant/inactive, or file for bankruptcy/insolvency within the next 12 months: **1.00 %**

Failure Score Formerly Financial Stress Score




Company's risk level is: **MODERATE**

Probability of failure over the next 12 months: **0.38 %**

Past 12 Months




Delinquency Score Formerly Commercial Credit Score




Company's risk level is: **HIGH**

Probability of delinquency over the next 12 months: **48.65 %**

Past 12 Months



PAYDEX ®



Days Beyond Terms : **12**

Past 24 Months



D&B Rating

Current Rating as of 03-02-2017

Previous Rating

Financial Strength

5A : US\$ 50,000,000 and over in Net Worth or Equity

Risk Indicator

2 : Low Risk

Financial Strength

5A : US\$ 50,000,000 and over in Net Worth or Equity

Risk Indicator

1 : Very Low Risk

Legal Events

Events	Occurrences	Last Filed
Bankruptcies	0	-
Judgements	0	-
Liens	6	11-20-2015
Suits	12	07-09-2018
UCC	40	02-16-2018

Trade Payments

Highest Past Due

US\$ 250,000

Highest Now Ow ing
US\$ 400,000

Total Trade Experiences
450

Largest High Credit
US\$ 2,000,000

Average High Credit
US\$ 34,755

Ownership

This company is a **Global Ultimate, Domestic Ultimate, Headquarters, Parent**

Financial Overview

Source: Edgar

Balance sheet 12-31-2017	Amount (In Single Units)	Last 3 Years
Net Worth:	US\$ 5,701,389,000	<div><div></div><div></div><div></div></div>
Total Current Assets:	US\$ 8,744,358,000	<div><div></div><div></div><div></div></div>
Total Assets:	US\$ 18,948,193,000	<div><div></div><div></div><div></div></div>
Total Current Liabilities:	US\$ 3,041,177,000	<div><div></div><div></div><div></div></div>
Working Capital/Net Current Assets:	US\$ 5,703,181,000	<div><div></div><div></div><div></div></div>
Total Liabilities:	US\$ 13,246,804,000	<div><div></div><div></div><div></div></div>
Long Term Liabilities:	US\$ 10,205,627,000	<div><div></div><div></div><div></div></div>
Profit & Loss 12-31-2017	Amount (In Single Units)	Last 3 Years
Sales:	US\$ 10,876,634,000	<div><div></div><div></div><div></div></div>
EBIT:	US\$ 1,399,786,000	<div><div></div><div></div><div></div></div>
EBITDA:	US\$ 2,177,271,000	<div><div></div><div></div><div></div></div>

Net Income:	US\$ 663,618,000	<div><div></div><div></div><div></div></div>
-------------	------------------	--

Key Business Ratios	Ratio for the Business
Current Ratio:	2.88
Quick Ratio:	0.88
Current Liabilities/Net Worth:	0.53
Sales to Net Working Capital:	1.91
Debt to Equity:	2.82

Country / Region Insight

United States



Risk Category




Second-quarter real GDP grows faster than originally estimated.

Risk Assessment

D&B Risk Assessment

Overall Business Risk



Maximum Credit Recommendation

US\$ 250,000


Dun & Bradstreet Thinks...

- Overall assessment of this organization over the next 12 months: **PAYMENT BEHAVIOR CONCERNS**
- Based on the predicted risk of business discontinuation: **EXHIBITING SOME FINANCIAL DIFFICULTIES**
- Based on the predicted risk of severely delinquent payments: **VERY HIGH POTENTIAL FOR SEVERELY DELINQUENT PAYMENTS**

The recommended limit is based on a high probability of severe delinquency or business failure. Guarantee Advised.

D&B Viability Rating

Portfolio Comparison Score



Level of Risk
Moderate-High

Rating Confidence Level
Robust Predictions

Probability of becoming no longer viable
1.00%

Percentage of businesses ranked with this score
10.00%

Average probability of becoming no longer viable
0.60%

Failure Score Formerly Financial Stress Score




- Low proportion of satisfactory payment experiences to total payment experiences
- Higher risk rating assigned by National Debt Rating Agency
- High proportion of slow payment experiences to total number of payment experiences
- Negative change in net worth
- UCC Filings reported
- Financial ratios indicate higher risk

Level of Risk
Moderate

Probability of Failure
0.38%

Average Probability of Failure for Businesses in D&B Database
0.48%

Business and Industry Trends




Failure Score



Industry Median Quartile



Delinquency Score Formerly Commercial Credit Score




- Evidence of negative trade
- Vendor payment commentary
- Recent amount past due
- Payment information indicates negative payment comments

Level of Risk
High

Probability of Delinquency
48.65%

Compared to Businesses in D&B Database
10.20%

Business and Industry Trends



Delinquency Score



Industry Median Quartile



PAYDEX®

Based on 24 months of data

72

Low Risk (100)

High Risk (0)

Risk of Slow Pay


Low

Payment Behavior

12 Days Beyond Terms

Business and Industry Trends

8092 - Kidney dialysis centers



PAYDEX®



Industry Median Quartile



Industry Upper Quartile



Industry Lower Quartile



D&B Rating

Current Rating as of 03-02-2017

Previous Rating

Financial Strength

5A : US\$ 50,000,000 and over in Net Worth or Equity

Risk Indicator

2 : Low Risk

Financial Strength

5A : US\$ 50,000,000 and over in Net Worth or Equity

Risk Indicator

1 : Very Low Risk

Trade Payments

Trade Payments Summary		
Overall Payment Behavior 12 Days Beyond Terms	% of Trade Within Terms 70%	Highest Past Due US\$ 250,000
Highest Now Owing: US\$ 400,000	Total Trade Experiences: 450 Largest High Credit: US\$ 2,000,000 Average High Credit: US\$ 34,755	Total Unfavorable Comments: 5 Largest High Credit: US\$ 20,000 Total Placed in Collections: 1 Largest High Credit: US\$ 0

Trade Payments By Credit Extended			
Range of Credit Extended (US\$)	Number of Payment Experiences	Total Value	% Within Terms
100,000 & over	17	US\$ 10,750,000	73
50,000 - 99,999	9	US\$ 525,000	55
15,000 - 49,999	35	US\$ 920,000	79
5,000 - 14,999	55	US\$ 362,500	72
1,000 - 4,999	96	US\$ 183,000	79
Less than 1,000	156	US\$ 49,600	63

Trade Payments By Industry								
Industry Category	Number of Payment Experiences	Largest High Credit (US\$)	% Within Terms (Expand to View)	1 - 30 Days Late (%)	31 - 60 Days Late (%)	61 - 90 Days Late (%)	91 + Days Late (%)	
▼ 07 - Agricultural Services	2	2,500						
0782 - Law n/garden services	2	2,500	50	38	0	12	0	
▼ 17 - Construction - Special Trade Contractors	4	30,000						
1796 - Erects building equip	4	30,000	61	0	39	0	0	
▼ 20 - Food and Kindred Products	1	250						
2087 - Mfg extracts/syrup	1	250	100	0	0	0	0	
▼ 26 - Paper and Allied Products	1	100						
2631 - Paperboard mill	1	100	0	100	0	0	0	
▼ 27 - Printing, Publishing and Allied Industries	8	40,000						
2711 - New spaper-print/publ	2	40,000	0	0	0	0	100	
2741 - Misc publishing	4	250	44	0	0	25	31	
2754 - Gravure printing	2	5,000	1	0	99	0	0	
▼ 28 - Chemicals and Allied Products	2	100,000						

2819 - Mfg inorganic chemcls	1	100,000	100	0	0	0	0
2841 - Mfg soap/detergents	1	500	0	0	0	0	100
▼ 32 - Stone, Clay, Glass, and Concrete Products	1	750					
3291 - Mfg abrasive products	1	750	0	0	0	100	0
▼ 34 - Fabricated Metal Products except Machinery and Transportation Equipment	1	100					
3479 - Coating/engrave svcs	1	100	0	0	0	0	100
▼ 35 - Industrial and Commercial Machinery and Computer Equipment	12	250,000					
3519 - Mfg combustion engine	1	2,500	50	0	0	0	50
3565 - Mfg packaging mach	3	500	0	0	0	0	100
3571 - Mfg computers	3	250,000	50	0	0	29	21
3585 - Mfg refrig/heat equip	3	10,000	75	0	0	0	25
3589 - Mfg service ind. mach	1	100	100	0	0	0	0
3596 - Mfg scales/balances	1	5,000	50	0	0	50	0
▼ 36 - Electronic and other electrical equipment and components except computer equipment	3	7,500					
3625 - Mfg relays/controls	1	500	100	0	0	0	0
3669 - Mfg alarm/signal dvcs	1	7,500	50	50	0	0	0
3679 - Mfg elect. components	1	750	100	0	0	0	0
▼ 38 - Measuring Analyzing and Controlling Instruments; Photographic Medical and Optical Goods; Watches and Clocks	13	750,000					
3823 - Mfg process controls	3	2,500	88	0	8	0	4
3825 - Mfg electric test prd	1	20,000	100	0	0	0	0
3826 - Mfg analytic instrmnt	1	250	0	0	0	50	50
3841 - Mfg medical instrmnt	5	45,000	84	0	0	15	1
3845 - Mfg electromedcl prdt	1	750,000	50	50	0	0	0
3861 - Mfg photograph equip	2	2,500	23	39	0	0	38
▼ 39 - Miscellaneous Manufacturing Industries	2	250					
3993 - Mfg signs/ad spectlys	2	250	0	83	0	0	17
▼ 42 - Motor Freight Transportation and Warehousing	3	7,500					
4213 - Trucking non-local	3	7,500	63	0	0	0	37
▼ 45 - Transportation by Air	1	500					
4581 - Airport/airport svcs	1	500	100	0	0	0	0
▼ 48 - Communications	11	600,000					
4812 - Radiotelephone commun	1	15,000	0	50	50	0	0
4813 - Telephone communictns	10	600,000	100	0	0	0	0
▼ 49 - Electric, Gas and Sanitary Services	59	10,000					
4911 - Electric services	40	10,000	89	9	0	2	0
4924 - Natural gas distrib	15	10,000	99	1	0	0	0
4925 - Gas production/distrib	1	250	100	0	0	0	0
4931 - Electric w/other svcs	1	2,500	100	0	0	0	0
4939 - Combination utilities	2	1,000	100	0	0	0	0
▼ 50 - Wholesale Trade - Durable Goods	51	2,000,000					
5012 - Whol motor vehicles	2	2,500	0	100	0	0	0

5021 - Whol furniture	6	1,000	66	27	7	0	0
5044 - Whol office equipment	4	1,000	100	0	0	0	0
5045 - Whol computers/softw r	1	2,000,000	100	0	0	0	0
5046 - Whol misc coml equip	1	100	100	0	0	0	0
5047 - Whol medical equip	3	1,000	92	8	0	0	0
5049 - Whol misc profsn eqpt	2	2,500	100	0	0	0	0
5065 - Whol electronic parts	2	1,000	5	95	0	0	0
5074 - Whol plumb/hydraulics	6	7,500	4	4	54	38	0
5075 - Whol heating/ac equip	1	45,000	100	0	0	0	0
5084 - Whol industrial equip	11	10,000	49	4	10	4	33
5085 - Whol industrial suppl	11	750,000	30	70	0	0	0
5088 - Whol transport equip	1	500	100	0	0	0	0
▼ 51 - Wholesale Trade - Nondurable Goods	30	400,000					
5112 - Whol office supplies	7	400,000	95	3	2	0	0
5113 - Whol service paper	9	60,000	51	1	44	0	4
5131 - Whol piece goods	1	100	100	0	0	0	0
5169 - Whol chemicals	7	2,500	75	6	0	19	0
5172 - Whol petroleum prdts	5	2,500	70	0	0	0	30
5199 - Whol nondurable goods	1	7,500	100	0	0	0	0
▼ 59 - Miscellaneous Retail	12	5,000					
5943 - Ret stationery	5	5,000	32	29	6	4	29
5961 - Ret mail-order house	2	250	100	0	0	0	0
5983 - Ret fuel oil dealer	1	750	0	100	0	0	0
5999 - Ret misc merchandise	4	5,000	97	0	0	0	3
▼ 60 - Depository Institutions	3	7,500					
6021 - Natnl commercial bank	2	7,500	40	30	0	30	0
6091 - Nondeposit trust	1	50	100	0	0	0	0
▼ 61 - Nondepository Credit Institutions	32	65,000					
6141 - Personal credit	1	55,000	100	0	0	0	0
6153 - Short-trm busn credit	10	65,000	49	22	25	0	4
6159 - Misc business credit	21	2,500	53	25	19	3	0
▼ 62 - Security and Commodity Brokers Dealers Exchanges and Services	10	1,000					
6211 - Security broker/deal	5	1,000	64	0	36	0	0
6282 - Investment advice	5	250	75	0	25	0	0
▼ 65 - Real Estate	1	10,000					
6531 - Real estate agent/mgr	1	10,000	50	50	0	0	0
▼ 72 - Personal Services	8	2,500					
7213 - Linen supply service	4	2,500	47	53	0	0	0
7218 - Industrial launderer	4	750	44	6	25	0	25
▼ 73 - Business Services	40	2,000,000					
7352 - Medical equip rental	1	7,500	50	50	0	0	0
7359 - Misc equipment rental	11	7,500	50	43	3	3	1
7363 - Help supply service	7	2,000,000	100	0	0	0	0
7371 - Custom programming	2	30,000	100	0	0	0	0

7372 - Prepackaged software	4	600,000	55	45	0	0	0
7374 - Data processing svcs	2	200,000	50	0	50	0	0
7379 - Misc computer service	2	250,000	50	50	0	0	0
7381 - Detective/guard svcs	5	35,000	74	12	0	14	0
7389 - Misc business service	6	500	58	42	0	0	0
▼ 75 - Automotive Repair, Services and Parking	4	1,000					
7513 - Truck rental/leasing	3	1,000	42	42	8	0	8
7514 - Passenger car rental	1	100	100	0	0	0	0
▼ 87 - Engineering Accounting Research Management and Related Services	8	2,000,000					
8733 - Noncoml research org.	1	2,000,000	50	50	0	0	0
8744 - Facilities support	4	35,000	70	30	0	0	0
8748 - Business consulting	3	15,000	2	0	98	0	0
▼ 91 - Executive Legislative and General Government except Finance	7	15,000					
9111 - Executive office	7	15,000	100	0	0	0	0
▼ 93 - Public Finance Taxation and Monetary Policy	14	15,000					
9311 - Public finance	14	15,000	100	0	0	0	0
▼ 96 - Administration of Economic Programs	1	250					
9651 - Reg misc coml sector	1	250	100	0	0	0	0
▼ 99 - Nonclassifiable Establishments	26	200,000					
9999 - Nonclassified	26	200,000	85	12	1	0	2

Trade Lines

Date of Experience	▼ Payment Status	Selling Terms	High Credit (US\$)	Now Owes (US\$)	Past Due (US\$)	Months Since Last Sale
09/18	Pays Promptly	-	100	0	0	Between 6 and 12 Months
09/18	Pays Promptly	-	50	50	0	1
09/18	Pays Promptly	-	50	50	0	1
09/18	Pays Promptly	-	50	50	0	1
09/18	Pays Promptly	-	50	50	0	1
09/18	Pays Slow 30+	-	2,500	0	0	Between 4 and 5 Months
09/18	Pays Slow 30+	-	2,500	0	0	Between 4 and 5 Months
09/18	Pays Slow 90+	-	250	250	250	1
08/18	Pays Promptly	N30	250,000	100,000	2,500	1
08/18	Pays Promptly	N60	55,000	15,000	0	1
08/18	Pays Promptly	N60	35,000	10,000	0	1
08/18	Pays Promptly	-	20,000	0	0	Between 4 and 5 Months
08/18	Pays Promptly	N30	20,000	10,000	0	1
08/18	Pays Promptly	-	10,000	7,500	0	1

08/18	Pays Promptly	-	10,000	2,500	0	1
08/18	Pays Promptly	-	10,000	5,000	0	1
08/18	Pays Promptly	-	7,500	0	0	Between 4 and 5 Months
08/18	Pays Promptly	-	5,000	2,500	0	1
08/18	Pays Promptly	-	5,000	0	0	Between 4 and 5 Months
08/18	Pays Promptly	-	5,000	2,500	0	1
08/18	Pays Promptly	-	2,500	2,500	-	1
08/18	Pays Promptly	-	2,500	2,500	0	1
08/18	Pays Promptly	-	2,500	2,500	-	1
08/18	Pays Promptly	-	2,500	2,500	-	1
08/18	Pays Promptly	-	2,500	2,500	0	1
08/18	Pays Promptly	-	2,500	0	0	Between 6 and 12 Months
08/18	Pays Promptly	-	2,500	2,500	-	1
08/18	Pays Promptly	-	2,500	2,500	0	1
08/18	Pays Promptly	-	2,500	2,500	0	1
08/18	Pays Promptly	N30	2,500	2,500	0	1
08/18	Pays Promptly	-	1,000	0	0	Between 4 and 5 Months
08/18	Pays Promptly	-	1,000	500	0	1
08/18	Pays Promptly	-	1,000	0	0	Between 6 and 12 Months
08/18	Pays Promptly	-	1,000	0	0	Between 6 and 12 Months
08/18	Pays Promptly	-	1,000	1,000	0	1
08/18	Pays Promptly	-	1,000	1,000	500	1
08/18	Pays Promptly	-	750	500	0	1
08/18	Pays Promptly	N30	750	0	0	Between 6 and 12 Months
08/18	Pays Promptly	-	750	500	0	1
08/18	Pays Promptly	-	750	0	-	1
08/18	Pays Promptly	-	500	500	0	1
08/18	Pays Promptly	-	500	100	0	1
08/18	Pays Promptly	-	500	100	0	1
08/18	Pays Promptly	-	500	0	0	Between 6 and 12 Months
08/18	Pays Promptly	-	250	100	0	1
08/18	Pays Promptly	-	250	100	0	1
08/18	Pays Promptly	-	100	100	0	1
08/18	Pays Promptly	-	100	100	0	1
08/18	Pays Promptly	-	100	0	0	Between 4 and 5 Months
08/18	Pays Promptly	-	100	0	0	Between 6 and 12 Months
08/18	Pays Promptly	-	50	50	0	1
08/18	Pays Promptly	-	50	50	0	1
08/18	Pays Promptly	-	50	0	0	Between 4 and 5 Months
08/18	Pays Prompt to Slow 15+	-	750	50	0	1

08/18	Pays Prompt to Slow 15+	-	500	250	0	1
08/18	Pays Prompt to Slow 30+	-	35,000	10,000	0	1
08/18	Pays Prompt to Slow 30+	-	7,500	2,500	100	1
08/18	Pays Prompt to Slow 30+	Lease Agreeemt	750	500	0	1
08/18	Pays Prompt to Slow 60+	-	200,000	0	0	Between 4 and 5 Months
08/18	Pays Prompt to Slow 60+	N30	65,000	20,000	5,000	1
08/18	Pays Prompt to Slow 60+	-	1,000	500	100	1
08/18	Pays Prompt to Slow 60+	N30	500	250	0	1
08/18	Pays Prompt to Slow 60+	-	500	0	0	Between 6 and 12 Months
08/18	Pays Prompt to Slow 60+	N30	500	0	0	Between 6 and 12 Months
08/18	Pays Prompt to Slow 90+	-	250	0	0	Between 6 and 12 Months
08/18	Pays Prompt to Slow 90+	N30	250	0	0	1
08/18	Pays Prompt to Slow 240+	-	10,000	500	0	1
08/18	Pays Prompt to Slow 240+	-	2,500	750	250	1
08/18	Pays Slow 5+	N60	55,000	20,000	20,000	1
08/18	Pays Slow 15+	-	5,000	2,500	2,500	1
08/18	Pays Slow 30+	N30	1,000	0	0	Between 2 and 3 Months
08/18	Pays Slow 30+	-	750	0	0	Between 6 and 12 Months
08/18	Pays Slow 15-45+	-	750	250	50	1
08/18	Pays Slow 30-120+	-	2,500	0	-	Between 6 and 12 Months
08/18	Pays Slow 120+	-	500	0	0	Between 6 and 12 Months
08/18	Pays Slow 30-120+	-	250	0	0	Between 6 and 12 Months
08/18	Pays Slow 120+	-	100	0	0	Between 6 and 12 Months
07/18	Pays Prompt to Slow 120+	-	5,000	0	0	1
07/18	Pays Slow 30-90+	N30	7,500	0	0	Between 6 and 12 Months
06/18	-	Sales COD	-	-	-	1

Legal Events

The following Public Filing data is for information purposes only and is not the official record. Certified copies can only be obtained from the official source.

Judgements	Liens	Suits	UCC Filings
------------	-------	-------	-------------

0

Latest Filing: -

6

Latest Filing: 11-20-2015

12

Latest Filing: 07-09-2018

40

Latest Filing: 02-16-2018

Events

Lien - Tax Lien

Filing Date	11-20-2015
Filing Number	15-1458377
Status	Open
Date Status Attained	11-20-2015
Received Date	12-16-2015
Amount	US\$ 167
Debtors	DAVITA INC, TACOMA, WA
Creditors	TAX COLLECTOR
Court	LOS ANGELES COUNTY RECORDER OF DEEDS, NORWALK, CA

Lien - Tax Lien

Filing Date	10-30-2015
Filing Number	1510300545
Status	Released
Date Status Attained	12-29-2015
Received Date	01-18-2016
Amount	US\$ 2,054
Debtors	RMS LIFELINE INC., VERNON HILLS, IL
Creditors	CA EMPLOYMENT DEVELOPMENT DEPARTMENT
Court	SACRAMENTO COUNTY RECORDERS OFFICE, SACRAMENTO, CA

Lien - Tax Lien

Filing Date	10-29-2015
Filing Number	15-7492584308
Status	Terminated
Date Status Attained	12-24-2015
Received Date	12-11-2017
Amount	US\$ 2,057
Debtors	RMS LIFELINE INC., VERNON HILLS, IL
Creditors	EMPLOYMENT DEVELOPMENT DEPARTMENT
Court	SECRETARY OF STATE/UCC DIVISION, SACRAMENTO, CA

Lien - Tax Lien

Filing Date	11-13-2013
Filing Number	13-1612996
Status	Open
Date Status Attained	11-13-2013
Received Date	10-05-2015
Amount	US\$ 162
Debtors	DAVITA INC, TACOMA, WA

Creditors	TAX COLLECTOR
Court	LOS ANGELES COUNTY RECORDER OF DEEDS, NORWALK, CA

Lien - Tax Lien

Filing Date	11-13-2013
Filing Number	13-1614863
Status	Open
Date Status Attained	11-13-2013
Received Date	10-05-2015
Amount	US\$ 162
Debtors	DAVITA INC, TACOMA, WA
Creditors	TAX COLLECTOR
Court	LOS ANGELES COUNTY RECORDER OF DEEDS, NORWALK, CA

Lien - Tax Lien

Filing Date	01-12-2012
Filing Number	12-0052611
Status	Open
Date Status Attained	01-12-2012
Received Date	10-05-2015
Amount	US\$ 163
Debtors	DAVITA INC, TACOMA, WA
Creditors	TAX COLLECTOR
Court	LOS ANGELES COUNTY RECORDER OF DEEDS, NORWALK, CA

Suit -

Filing Date	07-09-2018
Filing Number	20181003950CJC
Status	Pending
Date Status Attained	07-09-2018
Received Date	07-20-2018
Plaintiffs	LUIS RODRIGUEZ VILLAGOMEZ
Defendant	DAVITA INC, ANAHEIM, CA
Court	ORANGE COUNTY SUPERIOR COURT, SANTA ANA, CA

Suit -

Filing Date	09-08-2017
Filing Number	201700005919
Status	Pending
Date Status Attained	09-08-2017
Received Date	09-15-2017
Plaintiffs	RACHUBA, STEPHEN ESTATE, CROYDON, PA
Plaintiffs	RACHUBA, NOREEN ADMIN, CROYDON, PA
Defendant	DAVITA DIALYSIS CENTER, LANGHORNE, PA
Court	BUCKS COUNTY PROTHONOTARY, DOYLESTOWN, PA

Suit -

Filing Date	08-08-2017
Filing Number	201700004082C

Status	Pending
Date Status Attained	08-08-2017
Received Date	08-11-2017
Plaintiffs	WESTERN NEPHROLOGY & METABOLIC BONE DISEASE PC
Defendant	DAVITA INC, ROCKVILLE, MD
Defendant	AND OTHERS
Court	BALTIMORE CITY CIRCUIT COURT, BALTIMORE, MD

Suit -

Filing Date	04-17-2017
Filing Number	201700007795
Status	Pending
Date Status Attained	04-17-2017
Received Date	04-21-2017
Cause	Breach Of Contract
Plaintiffs	AETNA HEALTH MANAGEMENT LLC, HARTFORD, CT
Defendant	DAVITA INC
Court	MONTGOMERY COUNTY PROTHONOTARY , NORRISTOWN, PA

Suit -

Filing Date	12-14-2016
Filing Number	2016CV001559
Status	Pending
Date Status Attained	12-14-2016
Received Date	01-12-2017
Plaintiffs	WERNER, PAULA L, DE PERE, WI
Defendant	DAVITA HEALTHCARE PARTNERS INC, GOLDEN, CO
Defendant	AND OTHERS
Court	BROWN COUNTY CIRCUIT COURT, GREEN BAY , WI

Suit -

Filing Date	12-13-2016
Filing Number	201601201386
Status	Pending
Date Status Attained	12-13-2016
Received Date	12-16-2016
Cause	Medical malpractice
Plaintiffs	CHAROENPHORN 467, THONG, PHILADELPHIA, PA
Defendant	DAVITA, INC
Defendant	AND OTHERS
Court	PHILADELPHIA COUNTY COMMON PLEAS COURT, PHILADELPHIA, PA

Suit -

Filing Date	06-15-2016
Filing Number	201600601512
Status	Pending
Date Status Attained	06-15-2016
Received Date	06-17-2016
Cause	Negligence

Plaintiffs	JACKSON DEC, RICHARD, PHILADELPHIA, PA
Defendant	DAVITA, INC., DENVER, CO
Defendant	AND OTHERS
Court	PHILADELPHIA COUNTY COMMON PLEAS COURT, PHILADELPHIA, PA

Suit -

Filing Date	12-04-2014
Filing Number	14CI06209
Status	Pending
Date Status Attained	12-04-2014
Received Date	12-12-2014
Plaintiffs	CHARLES MATTHEWS
Defendant	DAVITA INC
Court	JEFFERSON COUNTY CIRCUIT COURT, LOUISVILLE, KY

Suit -

Filing Date	10-08-2014
Filing Number	201400018467
Status	Pending
Date Status Attained	10-08-2014
Received Date	10-10-2014
Plaintiffs	CASTELLI, ARMAND, MONROEVILLE, PA
Plaintiffs	CASTELLI, PATRICIA, MONROEVILLE, PA
Defendant	DAVITA HEALTHCARE PARTNERS INC.
Defendant	AND OTHERS
Court	ALLEGHENY COUNTY PROTHONOTARY, PITTSBURGH, PA

Suit -

Filing Date	05-15-2014
Filing Number	201400501702
Status	Pending
Date Status Attained	05-15-2014
Received Date	09-14-2015
Cause	Negligence
Plaintiffs	PHILLIPS, LARRY, PHILADELPHIA, PA
Defendant	DAVITA, INC., MALVERN, PA
Defendant	AND OTHERS
Court	PHILADELPHIA COUNTY COMMON PLEAS COURT, PHILADELPHIA, PA

UCC Filing - Original

Filing Date	05-05-2017
Filing Number	2017 2987516
Received Date	07-07-2017
Collateral	All Assets and proceeds
Secured Party	JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT, BROOKLYN, NY
Debtors	DAVITA MEDICAL HOLDINGS FLORIDA, INC
Filing Office	SECRETARY OF STATE/UCC DIVISION, DOVER, DE

UCC Filing - Original

Filing Date	05-05-2017
Filing Number	177584149066
Received Date	05-26-2017
Collateral	All Assets and proceeds
Secured Party	JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT, BROOKLYN, NY
Debtors	DAVITA MEDICAL MANAGEMENT, LLC
Filing Office	SECRETARY OF STATE/UCC DIVISION, SACRAMENTO, CA

UCC Filing - Original

Filing Date	05-05-2017
Filing Number	177584146033
Received Date	05-26-2017
Collateral	All Assets and proceeds
Secured Party	JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT, BROOKLYN, NY
Debtors	DAVITA MEDICAL HOLDINGS CALIFORNIA, LLC
Filing Office	SECRETARY OF STATE/UCC DIVISION, SACRAMENTO, CA

UCC Filing - Original

Filing Date	05-05-2017
Filing Number	201701141599
Received Date	05-23-2017
Collateral	All Assets and proceeds
Secured Party	JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT, BROOKLYN, NY
Debtors	DAVITA MEDICAL GROUP SOUTH FLORIDA, LLC
Filing Office	SECRETARY OF STATE/UCC DIVISION, TALLAHASSEE, FL

UCC Filing - Original

Filing Date	05-05-2017
Filing Number	20170052290C
Received Date	05-16-2017
Collateral	All Assets and proceeds
Secured Party	JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT, BROOKLYN, NY
Debtors	DAVITA HOLDING COMPANY , NEW MEXICO, LLC.
Filing Office	SECRETARY OF STATE/OPERATIONS BUREAU/UCC DIVISION, SANTA FE, NM

UCC Filing - Amendment

Filing Date	09-08-2016
Filing Number	20165474455
Received Date	10-18-2016
Original Filing Date	06-24-2014
Original Filing Number	2014 2496511
Secured Party	JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Debtors	DA VITA INC.
Filing Office	SECRETARY OF STATE/UCC DIVISION, DOVER, DE

UCC Filing - Original

Filing Date	03-25-2015
Filing Number	201508498249
Received Date	03-31-2015
Collateral	All Negotiable instruments including proceeds and products - All Inventory including proceeds and products - All Account(s) including proceeds and products - All Timber including proceeds and products - and OTHERS
Secured Party	BLACKHAWK BANK, ROCKFORD, IL
Debtors	COWELL DIALYSIS LLC, TACOMA, WA
Filing Office	SECRETARY OF STATE/UCC DIVISION, OLYMPIA, WA

UCC Filing - Original

Filing Date	01-05-2015
Filing Number	2015 0031814
Received Date	02-13-2015
Collateral	All Assets - All Fixtures
Secured Party	CREDIT AGRICOLE CORPORATE AND INVESTMENT BANK, NEW YORK, NY
Debtors	DAVITA HEALTHCARE PARTNERS INC.
Filing Office	SECRETARY OF STATE/UCC DIVISION, DOVER, DE

UCC Filing - Original

Filing Date	06-25-2014
Filing Number	1406250347833
Received Date	07-05-2014
Collateral	All Assets and proceeds
Secured Party	JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT, NEWARK, DE
Debtors	DAVITA OF NEW YORK, INC.
Filing Office	SECRETARY OF STATE/UCC DIVISION, ALBANY, NY

UCC Filing - Original

Filing Date	06-24-2014
Filing Number	2014 2496628
Received Date	08-01-2014
Collateral	All Assets and proceeds
Secured Party	JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT, NEWARK, DE
Debtors	DAVITA RX,LLC
Filing Office	SECRETARY OF STATE/UCC DIVISION, DOVER, DE

UCC Filing - Original

Filing Date	06-24-2014
Filing Number	2014 2496511
Received Date	08-01-2014
Collateral	All Assets and proceeds
Secured Party	JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT, NEWARK, DE
Debtors	DAVITA HEALTHCARE PARTNERS INC.
Filing Office	SECRETARY OF STATE/UCC DIVISION, DOVER, DE

The public record items contained in this report may have been paid, terminated, vacated or released prior to the date this report was printed. This information may not be reproduced in whole or in part by any means of reproduction

There may be additional UCC Filings in D&B's file on this company available by contacting 1-800-234-3867.

There may be additional suits, liens, or judgements in D&B's file on this company available in the U.S. Public Records Database, also covered under your contract. If you would like more information on this database, please contact the Customer Resource Center at 1-800-234-3867.

If it is indicated that there are defendants other than the report subject, the law suit may be an action to clear title to property and does not necessarily imply a claim for money against the subject.

A lien holder can file the same lien in more than one filing location. The appearance of multiple liens filed by the same lien holder against a debtor may be indicative of such an occurrence.

Special Events

08-03-2018

EARNINGS UPDATE: According to published reports, comparative operating results for the 6 months ended June 30, 2018: Revenue of \$5,736,397,000, Net Income of \$531,551,000; compared to Revenue of \$5,330,650,000, Net Income of \$661,910,000 for the comparable period in the prior year. **MERGER/ACQUISITION:** According to published reports, DaVita Inc., DUNS 883073371, (Denver, CO) announced that it has acquired Porto Seguro Centros Medicos Ltda.

07-31-2018

ANNOUNCED WORK FORCE CHANGES: According to published reports, DaVita Inc., announced that it is laying off 109 employees at a prescription-drug distribution facility in Orlando. The layoffs come after a sale involving its DaVita Rx prescription-drug unit to Walgreens. The cuts impact workers at the facility at 2252 Commerce Park Dr. in Orlando, where employees packaged prescription pharmaceuticals to be distributed to patients undergoing dialysis treatments. Employees will be let go between Sept. 23 and Dec. 3.

06-07-2018

SALE OF ASSET: According to published reports, Paladina Health, DUNS 078409479, (Denver, CO), announced that New Enterprise Associates, DUNS 093010353, (Lutherville Timonium, MD), has acquired the wholly owned subsidiary from DaVita Inc., DUNS 883073371, (Denver, CO).

Company Profile

Company Overview

D-U-N-S

88-307-3371

Legal Form

Mailing Address

PO Box 2037

Tacoma, WA 98401

Annual Sales

US\$ 10,876,634,000

Employees

Corporation (US)	United States	70,335 (100 here)
History Record	Telephone	Age (Year Started)
Clear	(303) 405-2100	24 years (1994)
Date Incorporated	Website	Named Principal
04-03-1994	www.davitahealthcarepartners.com	Kent J Thiry, CHB-CEO
State of Incorporation	Present Control Succeeded	Line of Business
Delaware	1994	Kidney dialysis centers
Ownership		
Public: DVA (NYS)		

Business Registration	
Corporate and business registrations reported by the secretary of state or other official source as of: 04-21-2017 This data is for informational purposes only, certification can only be obtained through the Office of the Secretary of State.	
Registered Name	DAVITA INC.
Corporation Type	Corporation (US)
Business Commenced On	1994
State of Incorporation	DELAWARE
Date Incorporated	04-04-1994
Registration ID	2391269
Registration Status	STATUS NOT AVAILABLE
Filing Date	04-04-1994
Where Filed	SECRETARY OF STATE/CORPORATIONS DIVISION
Registered Agent	
Name	CORPORATION SERVICE COMPANY
Address	2711 CENTERVILLE RD SUITE 400, WILMINGTON, DE, 198080000

Principals
Officers
KENT J THIRY, CHB-CEO+
JAMES K HILGER, CAO
KATHLEEN A WATERS, CLO
JEANINE M JIGANTI, CCO
JOEL ACKERMAN, SR V PRES FIN-CFO
LEANNE M ZUMWALT, GROUP V PRES PURCHASING & PUBLIC AFFAIRS
Directors
THE OFFICER(S) and Pamela M Arway, Charles G Berg, Carol A Davidson, Barbara J Desoer, Pascal Desroches, Paul J Diaz, Peter T Grauer, John M Nehra, William L Roper, Roger J Valine and Phyllis R Yale.

Company Events
The following information was reported on: 08-29-2018

The Delaware Secretary of State's business registrations file showed that DaVita Inc. was registered as a Corporation on April 4, 1994, under the file registration number 2391269.

Business started 1994.

The company was formed in 1994 under the name Total Renal Care Holdings, Inc. Effective October 9, 2000, the company changed its name from Total Renal Care Holdings to DaVita Inc.

On November 1, 2012, the company changed its name from DaVita Inc. to DaVita HealthCare Partners Inc. Effective September 1, 2016, the company changed its name to DaVita Inc.

The company's common stock is traded on the New York Stock Exchange (NYSE) under the symbol "DVA". As of January 31, 2017, there were 9,853 holders of record of the company's common stock. As of March 31, 2016, the most recent date available, those shareholders identified by the company as beneficially owning 5% or more of the outstanding shares were: The Vanguard Group, Inc. (6.97%); BlackRock Inc. (5.96%) and Warren E Buffett (18.69%). As of the same date, officers and directors as a group beneficially owns 2.1% of the outstanding shares.

RECENT EVENTS:

On August 7, 2018, sources stated that DaVita Inc., Denver, CO, through its subsidiary DaVita Healthcare Brasil Servicos Medicos Ltda., Sao Paulo, Brazil, has acquired Porto Seguro Centros Medicos Ltda., Sao Paulo, Brazil, on July 26, 2018. Terms of the deal were not disclosed. Further details are unavailable.

On June 20, 2018, sources stated that New Enterprises Associates, Inc., Lutherville Timonium, MD, has acquired Paladina Health, LLC, Denver, CO, from Davita Inc., Denver, CO, on June 6, 2018. With the acquisition, Paladina Health, LLC will now operate as a subsidiary of New Enterprises Associates, Inc. Employees and management were retained. Terms of the deal were approximately \$100 million. Further details are unavailable.

On December 8, 2017, an inside source stated that Davita Medical Group New Mexico, LLC, d/b/a DaVita Medical Group, Albuquerque, NM, a subsidiary of DaVita Inc., Denver, CO, has acquired Northwest Physicians Network, Tacoma, WA, on November 28, 2017. With the acquisition, Northwest Physicians Network has ceased to operate as a legal entity, and the location will now operate as a branch of Davita Medical Group New Mexico, LLC, d/b/a Northwest Physicians Network. Terms of the deal were not disclosed. Further details are unavailable.

On June 7, 2017, sources stated that Davita Inc., Denver, CO, has acquired Centrumdializa.pl., Sosnowiec, Poland, on May 25, 2017. Terms of the deal were not disclosed. Further details are unavailable.

On May 22, 2017, sources stated that Davita Inc., Denver, CO, has acquired Purity Dialysis Centers, Inc., Delafield, WI, on May 8, 2017. With the acquisition, Purity Dialysis Centers, Inc. will now operate as a subsidiary of Davita Inc. Employees and management were retained. Terms of the transaction were not disclosed. Further details are unavailable.

On May 19, 2017, sources stated that Orion Medical Enterprises, Inc., d/b/a Physicians Dialysis, Miami, FL, has closed on the acquisition of seven dialysis facilities located in New Jersey and Texas from DaVita Inc., Denver, CO, on May 4, 2017. Repeated attempts to contact management to confirm the transaction were unsuccessful. Terms of the deal were not disclosed. Further details are unavailable.

On May 17, 2017, sources stated that Davita Inc., Denver, CO, has acquired 100% of the interest in Renal Ventures Management, LLC, Lakewood, CO, on May 2, 2017. With the acquisition, Renal Ventures Management, LLC will now operate as a wholly owned subsidiary of Davita Inc. Employees and management were retained. Terms include a purchase price of \$360,000 in cash, subject to certain post-closing adjustments. Renal Ventures Management, LLC, 38 outpatient dialysis centers in six states. As a part of this transaction, Davita Inc., was required to divest seven outpatient dialysis centers. Further details are unavailable.

On May 16, 2017, sources stated that Healthcare Partners Nevada LLC, Las Vegas, NV, a subsidiary of DaVita, Inc., Denver, CO, has acquired MedSource Management Group, LLC d/b/a WellHealth Quality Care, Reno, NV, on May 2, 2017. With the acquisition, MedSource Management Group, LLC will now operate as a subsidiary of Healthcare Partners Nevada LLC. Employees and management were retained. Terms of the deal were not disclosed. Further details are unavailable.

On February 1, 2017, the company, through its undisclosed affiliate has completed the acquisition of Mountain View Medical Group P.C.

On September 2, 2016, DaVita Kidney Care, a division of the company, has acquired two dialysis treatment centers in Sao Paulo, Brazil.

During 2016, the company acquired eight dialysis centers in the U.S., 21 dialysis centers outside the U.S., and other medical businesses for a total of \$170,169 in net cash, earn-outs of \$1,511, and deferred purchase price and liabilities assumed of \$18,373.

On March 1, 2016, the company completed its acquisition of The Everett Clinic Medical Group (TEC) pursuant to an agreement and plan of merger dated November 23, 2015, whereby TEC became a 100% consolidated subsidiary of HCP. The total consideration paid at closing for all outstanding common units of TEC was approximately \$398,093, net of cash acquired, plus the assumption of certain liabilities totaling approximately \$7,287, subject to certain post-closing adjustments.

During 2015, the company acquired dialysis-related and other ancillary businesses consisting of six dialysis centers in the U.S., 21 dialysis centers outside of the U.S., three vascular access centers, and other medical businesses for a total of \$96,469 in net cash and deferred purchase price and earn-outs of \$8,395.

During 2015, the company's HCP business acquired three family practices, one management services organization, two primary care practices, and six private medical practices.

KENT J THIRY. Director of the company. He has been the company's Chairman of the Board since June 2015 and from October 1999 until November 2012, and its CEO since October 1999. He also served in other various positions with the company since joining in 1999 until 2015.

JAMES K HILGER. He continues to serve as its CAO, a position he has held since April 2010 after having previously served in other various roles with the company since 2005.

KATHLEEN A WATERS. She became the company's Chief Legal Officer (CLO) in May 2016. Prior to joining the company, she was Senior Vice President, General Counsel and Secretary of Health Net, Inc. from April 2015 to March 2016. She was a Partner in Morgan, Lewis & Bockius LLP's litigation practice from 2003 to 2015. She also was the leader of that firm's Los Angeles litigation group and co-leader of the healthcare group.

JEANINE M JIGANTI. She became the company's Chief Compliance Officer (CCO) in March 2013 after serving in other positions since 2012. Prior to joining the company, she served as CCO for Takeda Pharmaceuticals North America from October 2005 to March 2012. Additionally, she served as CCO for several of Takeda Pharmaceutical Company Limited's affiliates including Takeda Global Research and Development and Takeda Pharmaceuticals International Operations.

JOEL ACKERMAN. He has been appointed as the company's CFO on January 5, 2017. He has also been Senior Vice President, Finance February 21, 2017. Prior to joining the company, he was the CEO at Champions Oncology since October 2010. In the first quarter of the year, he will become the Non-Executive Chairman of Champions Oncology. He is a founder of and investor in Guidon Partners LP, founded in November 2014. He was also a Managing Director at Warburg Pincus.

LEANNE M ZUMWALT. She became the Group Vice President-Purchasing and Public Affairs of the company in July 2011. From 2000 to 2011, she has held several positions with the company.

PAMELA MARWAY. Director since 2009. From 2005 to 2007, she served as the President of American Express International, Japan, Asia-Pacific, Australia region.

CHARLES G BERG. Director since 2007. He served as the Executive Chairman of WellCare Health Plans, Inc. (WellCare), from January 2008 to December 2010.

CAROL A DAVIDSON. Director since 2010. From January 2004 until his retirement in September 2012, he served as the Senior Vice President, Controller and CAO of Tyco International Ltd (Tyco).

BARBARA J DESOER. Director since 2015. She currently serves as the CEO of Citibank, NA since April 2014.

PASCAL DESROCHES. Director since 2017. He served as CFO for Turner Broadcasting.

PAUL J DIAZ. Director since 2007. He serves as the Executive Vice Chairman of Kindred Healthcare, Inc., a position he has held since March 2015. Since August 2014, he has served as a Partner at Guidon Partners LP.

PETER T GRAUER. Director since 1994. He serves as the company's Lead Independent Director since 2003. He has been the Chairman of the Board of Bloomberg, Inc. since April 2001, Treasurer since March 2001 and was its CEO from March 2002 until July 2011.

JOHN M NEHRA. Director since 2000. From 1989 until his retirement in August 2014, he was affiliated with New Enterprise Associates (NEA).

WILLIAM L ROPER. Director since 2001. He has been the CEO of the University of North Carolina (UNC) Health Care System, Dean of the UNC School of Medicine and Vice Chancellor for Medical Affairs of UNC since March 2004.

ROGER J VALINE. Director since 2006. From January 1992 to his retirement in June 2006, he served as both the President and CEO of Vision Service Plan (VSP).

PHYLLIS R YALE. Director since 2016. He has been an Advisory Partner with Bain & Company, Inc. since July 2010.

ANNOUNCED MERGER/ACQUISITION: On August 9, 2016, the company entered into an amendment to its agreement to acquire Colorado-based Renal Ventures Limited, LLC (Renal Ventures). As a result of the amended agreement, the company will acquire a 100 percent interest in all 38 outpatient dialysis centers owned by Renal Ventures, including one new center under construction, and a fifty-one percent interest in one vascular access clinic. The purchase price will be approximately \$360,000 in cash, subject to, among other things, adjustments for certain items such as working capital.

The transaction is subject to approval by the Federal Trade Commission (FTC), including Hart-Scott-Rodino antitrust clearance. The company

anticipates that it will be required by the FTC to divest some outpatient dialysis centers as a condition of the transaction. The company expects the transaction to close in mid 2017.

Business Activities And Employees

The following information was reported on: 08-29-2018

Business Information

Description	<p>The company provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). It operates through two divisions, DaVita Kidney Care and DaVita Medical Group.</p> <p>The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers, as well as patient and physician focused integrated health care delivery and management services. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services.</p> <p>Revenues are generally by third party insurance payments. Sells to general public. Territory : International.</p>
Employees	70,335 which includes officer(s). 100 employed here.
Financing Status	Secured
Financial Condition	Strong
Seasonality	Nonseasonal.
Facilities	Occupies 356,000 sq. ft. in a building.

SIC/NAICS Information

SIC Codes	SIC Description	Percentage of Business
8092	Kidney dialysis centers	-
80920000	Kidney dialysis centers	-
80930000	Specialty outpatient clinics, nec	-

NAICS Codes	NAICS Description
621492	Kidney Dialysis Centers
621498	All Other Outpatient Care Centers

Government Activity

Activity Summary

Borrower(Dir/Guar)	No
Administrative Debt	No
Contractor	Yes


Grantee	No
Party excluded from federal program(s)	No

Financials

Income Statement

Source: Edgar | Currency: All figures shown in USD unless otherwise stated


Annual



	Fiscal Consolidated 12-31-2017	Fiscal Consolidated 12-31-2016	Fiscal Consolidated 12-31-2015	Last 3 Years
Total Current Assets				
Sales (Revenue)	10,876,634,000	10,707,467,000	9,982,245,000	<div><div></div><div></div><div></div></div>
Cost of Revenue	7,640,005,000	7,431,582,000	6,856,062,000	<div><div></div><div></div><div></div></div>
Gross Profit	3,236,629,000	3,275,885,000	3,126,183,000	<div><div></div><div></div><div></div></div>
Sales and General Admin	1,064,026,000	1,072,841,000	1,031,125,000	<div><div></div><div></div><div></div></div>
Research and Development Expense	-	-	-	<div><div></div><div></div><div></div></div>
Non-Recurring Expenses	324,397,000	55,085,000	13,306,000	<div><div></div><div></div><div></div></div>
Other Operating Items	559,911,000	509,497,000	463,905,000	<div><div></div><div></div><div></div></div>
Operating Income	1,812,755,000	2,029,710,000	1,136,766,000	<div><div></div><div></div><div></div></div>
Net Total Other Income and Expenses	120,131,000	(32,231,000)	(943,379,000)	<div><div></div><div></div><div></div></div>
Earnings Before Interest and Taxes	1,399,786,000	1,623,105,000	688,387,000	<div><div></div><div></div><div></div></div>
Interest Expense	-	-	-	<div><div></div><div></div><div></div></div>
Earnings Before Tax	1,399,786,000	1,623,105,000	688,387,000	<div><div></div><div></div><div></div></div>
Income Tax Expense	323,859,000	431,761,000	207,510,000	<div><div></div><div></div><div></div></div>
Equity Earnings or Loss	(8,640,000)	16,874,000	13,919,000	<div><div></div><div></div><div></div></div>
Minority Interest Expense	166,937,000	153,208,000	157,678,000	<div><div></div><div></div><div></div></div>
Net Income from Continuing Operations	1,075,927,000	1,191,344,000	480,877,000	<div><div></div><div></div><div></div></div>

Discontinued Operations	(245,372,000)	(158,262,000)	(53,467,000)	
Effect of Accounting Changes	-	-	-	-
Extraordinary Items	-	-	-	-
Net Income	663,618,000	879,874,000	269,732,000	
Preferred Stocks & Other Adjustments	-	-	-	-
Net Income Applicable to Common Shares	663,618,000	879,874,000	269,732,000	

Quarterly



Total Current Assets	Q2 06-30-2018	Q1 03-31-2018	Q3 09-30-2017	Q2 06-30-2017	Last 4 Quarters
Sales (Revenue)	2,886,953,000	2,849,444,000	6,166,941,000	2,699,399,000	
Cost of Revenue	2,069,089,000	2,035,585,000	4,761,997,000	1,894,664,000	
Gross Profit	817,864,000	813,859,000	1,404,944,000	804,735,000	
Sales and General Admin	264,094,000	266,529,000	121,595,000	262,796,000	
Research and Development Expense	-	-	-	-	-
Non-Recurring Expenses	12,251,000	(6,000,000)	648,974,000	9,892,000	
Other Operating Items	147,079,000	142,799,000	320,617,000	140,026,000	
Operating Income	438,192,000	410,686,000	(193,095,000)	391,196,000	
Net Total Other Income and Expenses	(83,741,000)	(108,934,000)	(614,299,000)	(103,136,000)	
Earnings Before Interest and Taxes	320,494,000	301,752,000	(297,696,000)	288,060,000	
Interest Expense	-	-	-	-	-
Earnings Before Tax	320,494,000	301,752,000	(297,696,000)	288,060,000	
Income Tax Expense	83,868,000	70,737,000	(107,575,000)	101,915,000	
Equity Earnings or Loss	9,795,000	155,000	2,845,000	(825,000)	

Minority Interest Expense	39,046,000	46,543,000	42,442,000	34,624,000	<div><div></div><div></div><div></div><div></div><div></div></div>
Net Income from Continuing Operations	236,626,000	231,015,000	(317,078,000)	186,145,000	<div><div></div><div></div><div></div><div></div><div></div></div>
Discontinued Operations	69,696,000	(5,786,000)	18,087,000	(24,520,000)	<div><div></div><div></div><div></div><div></div><div></div></div>
Effect of Accounting Changes	-	-	-	-	-
Extraordinary Items	-	-	-	-	-
Net Income	267,276,000	178,686,000	(214,476,000)	127,001,000	<div><div></div><div></div><div></div><div></div><div></div></div>
Preferred Stocks & Other Adjustments	-	-	-	-	-
Net Income Applicable to Common Shares	267,276,000	178,686,000	(214,476,000)	127,001,000	<div><div></div><div></div><div></div><div></div><div></div></div>

Statement Information

Profit and Loss Information

From JAN 01 2018 to JUN 30 2018 sales \$5,736,397,000; cost of goods sold \$4,104,674,000. Gross profit \$1,631,723,000; operating expenses \$834,852,000. Operating income \$796,871,000; other income \$122,493,000; other expenses \$233,208,000; net income before taxes \$686,156,000; Federal income tax \$154,605,000; net income \$531,551,000.

Source Information

Statement obtained from Securities And Exchange Commission. Prepared from books without audit.


Statement Explanation













Explanations: The net worth of this company includes intangibles; Other Long Term Liabilities consist of noncontrolling interests and other long-term liabilities; Adjustments consists of accumulated other comprehensive loss and noncontrolling interests.











Balance Sheet





Source: Edgar | Currency: All figures shown in USD unless otherwise stated

Annual



Assets	Fiscal Consolidated 12-31-2017	Fiscal Consolidated 12-31-2016	Fiscal Consolidated 12-31-2015	Last 3 Years
Cash and Cash Equivalents	508,234,000	674,776,000	1,499,116,000	
Short Term Investments	43,516,000	306,981,000	408,084,000	
Net Trade Receivables	2,137,109,000	1,792,106,000	2,220,183,000	
Inventory	181,799,000	160,419,000	185,575,000	
Other Current Assets	5,873,700,000	1,060,466,000	190,322,000	
Total Current Assets	8,744,358,000	3,994,748,000	4,503,280,000	
Fixed Assets	3,149,213,000	8,116,256,000	2,788,740,000	
Long Term Investments	283,229,000	522,036,000	167,490,000	
Deferred Long Term Asset Charges	-	-	-	-
Other Assets	47,287,000	33,857,000	73,560,000	
Goodwill	6,610,279,000	6,015,375,000	9,294,479,000	
Total Assets	18,948,193,000	18,755,776,000	18,514,875,000	
Accumulated Amortization	-	-	-	-
Intangible Assets	113,827,000	73,504,000	1,687,326,000	

Liabilities	Fiscal Consolidated 12-31-2017	Fiscal Consolidated 12-31-2016	Fiscal Consolidated 12-31-2015	Last 3 Years
Accounts Payable	1,125,232,000	1,164,577,000	1,255,876,000	
Short Term and Current Long Term Debt	178,213,000	160,262,000	461,139,000	
Other Current Liabilities	1,737,732,000	1,386,125,000	682,123,000	
Total Current Liabilities	3,041,177,000	2,710,964,000	2,399,138,000	
Long Term Debt	9,158,018,000	8,944,676,000	9,001,308,000	
Deferred Long Term Liability Charges	486,247,000	530,869,000	726,962,000	
Negative Goodwill	-	-	-	-
Minority Interest	196,037,000	201,694,000	213,392,000	
Other Liabilities	365,325,000	746,268,000	439,229,000	
Misc Stocks, Options & Warrants	1,011,360,000	973,258,000	864,066,000	
Total Liabilities	13,246,804,000	13,134,471,000	12,780,029,000	

Shareholder Equity	Fiscal Consolidated 12-31-2017	Fiscal Consolidated 12-31-2016	Fiscal Consolidated 12-31-2015	Last 3 Years
Preferred Stocks	-	-	-	-
Common Stocks	182,000	195,000	217,000	
Retained Earnings	3,633,713,000	3,710,313,000	4,356,835,000	
Treasury Stocks	-	-	544,772,000	-
Capital Surplus	1,042,899,000	1,027,182,000	1,118,326,000	
Other Equity	13,235,000	(89,643,000)	(59,826,000)	

Total Equity


4,690,029,000

4,648,047,000

4,870,780,000



Quarterly




Assets	Q2 06-30-2018	Q1 03-31-2018	Q3 09-30-2017	Q2 06-30-2017	Last 4 Quarters
Cash and Cash Equivalents	480,148,000	447,618,000	846,110,000	711,997,000	
Short Term Investments	4,528,000	4,602,000	137,358,000	211,436,000	
Net Trade Receivables	2,337,450,000	2,265,164,000	2,690,448,000	2,698,567,000	
Inventory	112,729,000	125,555,000	154,422,000	199,304,000	
Other Current Assets	6,150,507,000	5,830,616,000	205,211,000	202,464,000	
Total Current Assets	9,085,362,000	8,673,555,000	4,033,549,000	4,023,768,000	
Fixed Assets	3,229,098,000	3,185,223,000	3,386,056,000	3,248,030,000	
Long Term Investments	283,220,000	279,908,000	665,182,000	657,161,000	
Deferred Long Term Asset Charges	-	-	-	-	-
Other Assets	59,070,000	51,728,000	61,642,000	60,140,000	
Goodwill	6,678,559,000	6,638,592,000	9,415,877,000	9,889,791,000	
Total Assets	19,435,564,000	18,942,372,000	19,013,339,000	19,341,784,000	
Accumulated Amortization	-	-	-	-	-
Intangible Assets	100,255,000	113,366,000	1,451,033,000	1,462,894,000	
Liabilities	Q2 06-30-2018	Q1 03-31-2018	Q3 09-30-2017	Q2 06-30-2017	Last 4 Quarters
Accounts Payable	1,175,364,000	963,916,000	1,356,589,000	1,315,341,000	
Short Term and Current Long Term Debt	1,768,514,000	184,136,000	590,081,000	572,710,000	

Other Current Liabilities	1,839,900,000	1,799,471,000	928,123,000	885,274,000	
Total Current Liabilities	4,783,778,000	2,947,523,000	2,874,793,000	2,773,325,000	
Long Term Debt	8,175,573,000	9,279,885,000	8,908,703,000	8,910,814,000	
Deferred Long Term Liability Charges	526,425,000	507,226,000	685,598,000	855,159,000	
Negative Goodwill	-	-	-	-	-
Minority Interest	205,323,000	201,401,000	184,548,000	187,582,000	
Other Liabilities	418,123,000	391,156,000	548,226,000	520,886,000	
Misc Stocks, Options & Warrants	1,047,158,000	1,034,501,000	1,026,890,000	1,009,704,000	
Total Liabilities	14,109,222,000	13,327,191,000	13,201,868,000	13,247,766,000	
Shareholder Equity	Q2 06-30-2018	Q1 03-31-2018	Q3 09-30-2017	Q2 06-30-2017	Last 4 Quarters
Preferred Stocks	-	-	-	-	-
Common Stocks	183,000	183,000	195,000	195,000	
Retained Earnings	4,088,043,000	3,820,767,000	4,070,535,000	4,285,011,000	
Treasury Stocks	809,900,000	298,377,000	348,801,000	231,674,000	
Capital Surplus	1,022,783,000	1,030,772,000	1,059,176,000	1,058,090,000	
Other Equity	(21,925,000)	27,335,000	3,476,000	(27,308,000)	
Total Equity	4,279,184,000	4,580,680,000	4,784,581,000	5,084,314,000	

Cash Flow


Source: Edgar | Currency: All figures show n in USD unless otherw ise stated

Annual



	Fiscal Consolidated 12-31-2017	Fiscal Consolidated 12-31-2016	Fiscal Consolidated 12-31-2015	Last 3 Years
Depreciation	777,485,000	720,252,000	638,024,000	
Net Income Adjustments	167,085,000	(6,981,000)	925,698,000	
Changes in Liabilities	(90,474,000)	364,556,000	274,539,000	
Changes in Accounts Receivables	(273,459,000)	(206,278,000)	(170,106,000)	
Changes in Inventories	(18,625,000)	22,920,000	(48,313,000)	
Changes in Other Operating Activities	573,625,000	51,681,000	(515,907,000)	
Net Cash Flows - Operating Activities	1,907,449,000	1,963,444,000	1,557,200,000	
Capital Expenditures	(905,250,000)	(829,095,000)	(707,998,000)	
Investments	250,062,000	126,558,000	(97,032,000)	
Other Cash Flows from Investing Activities	(711,543,000)	(499,131,000)	(76,754,000)	
Net Cash Flows - Investing Activities	(1,366,731,000)	(1,201,668,000)	(881,784,000)	
Dividends Paid	(211,467,000)	(192,401,000)	(174,635,000)	
Sale and Purchase of Stock	(709,638,000)	(1,048,201,000)	(535,518,000)	
Net Borrowings	154,848,000	(124,630,000)	543,026,000	
Other Cash Flows from Financing Activities	-	-	-	
Net Cash Flows - Financing Activities	(766,257,000)	(1,351,981,000)	(138,970,000)	
Effect of Exchange Rate	254,000	4,276,000	(2,571,000)	
Change in Cash and Cash Equivalents	(166,542,000)	(570,141,000)	508,020,000	

Quarterly



Changes in Inventories	14,011,000	57,621,000	45,339,000	(22,158,000)
Changes in Other Operating Activities	(210,667,000)	(15,780,000)	53,682,000	(18,041,000)
Net Cash Flows - Operating Activities	562,036,000	362,539,000	549,482,000	149,886,000
Capital Expenditures	(241,534,000)	(232,443,000)	(240,889,000)	(184,405,000)
Investments	(7,225,000)	30,362,000	69,669,000	101,764,000
Other Cash Flows from Investing Activities	24,823,000	1,953,000	(84,406,000)	(518,979,000)
Net Cash Flows - Investing Activities	(223,936,000)	(200,128,000)	(255,626,000)	(601,620,000)
Dividends Paid	(48,539,000)	(45,467,000)	(49,388,000)	(72,759,000)
Sale and Purchase of Stock	(501,933,000)	(281,753,000)	(70,835,000)	(205,591,000)
Net Borrowings	467,110,000	104,673,000	(44,431,000)	(27,891,000)
Other Cash Flows from Financing Activities	-	-	0	-
Net Cash Flows - Financing Activities	(83,362,000)	(222,547,000)	(164,654,000)	(306,241,000)
Effect of Exchange Rate	(10,141,000)	6,668,000	1,257,000	1,372,000
Change in Cash and Cash Equivalents	32,530,000	(71,302,000)	163,179,000	(764,830,000)

Financial Ratios

Source: D&B | Currency: All figures shown in USD unless otherwise stated

Annual

Solvency Ratios	Fiscal Consolidated 12-31-2017	Fiscal Consolidated 12-31-2016	Fiscal Consolidated 12-31-2015
Current Ratio	2.88	1.47	1.88
Quick Ratio	0.88	1.02	1.72
Current Liabilities to Net Worth (%)	64.84	58.32	49.26
Total Liabilities/Net Worth (%)	282.45	282.58	262.38
Current Liabilities to Inventory (%)	1,672.82	1,689.93	1,292.81
Fixed Assets to Net Worth (%)	67.15	174.62	57.25
Cash Ratio	0.18	0.36	0.79
Efficiency Ratios	Fiscal Consolidated 12-31-2017	Fiscal Consolidated 12-31-2016	Fiscal Consolidated 12-31-2015
Accounts Payable to Sales Ratio	0.10	0.11	0.13
Sales to Working Capital Ratio	1.91	8.34	4.74
Sales To Inventory (%)	5,982.78	6,674.69	5,379.09
Assets/Sales	174.21	175.17	185.48
ROCE (%)	8.80	10.12	4.27
Profitability Ratios	Fiscal Consolidated 12-31-2017	Fiscal Consolidated 12-31-2016	Fiscal Consolidated 12-31-2015
Return On Net Worth (%)	14.15	18.93	5.54
Return on Assets (%)	3.50	4.69	1.46
Return on Sales (%)	12.87	15.16	6.90

Gross Profit Margin (%)	29.76	30.59	31.32
Operating Margin (%)	16.67	18.96	11.39
Pre-Tax Profit Margin (%)	12.87	15.16	6.90
Profit Margin (%)	6.10	8.22	2.70
Pre-Tax Return on Equity (%)	29.85	34.92	14.13
After Tax Return on Equity (%)	14.15	18.93	5.54
Operating Income to Interest Ratio	-	-	-

Leverage Ratios	Fiscal Consolidated 12-31-2017	Fiscal Consolidated 12-31-2016	Fiscal Consolidated 12-31-2015
EBITDA to EBIT Ratio	1.56	1.44	1.93
Debt to Income Ratio	19.96	14.93	47.38
Debt to Equity Ratio	2.82	2.83	2.62
Equity Ratio (%)	24.75	24.78	26.31
Interest Coverage Ratio	-	-	-
Interest Coverage to EBITDA Ratio	-	-	-

Quarterly

Solvency Ratios	Q2 06-30-2018	Q1 03-31-2018	Q3 09-30-2017	Q2 06-30-2017
Current Ratio	1.90	2.94	1.40	1.45
Quick Ratio	0.59	0.92	1.28	1.31
Current Liabilities to Net Worth (%)	111.79	64.35	60.08	54.55
Total Liabilities/Net Worth (%)	329.72	290.94	275.93	260.56
Current Liabilities to Inventory (%)	4,243.61	2,347.60	1,861.65	1,391.50
Fixed Assets to Net Worth (%)	75.46	69.54	70.77	63.88
Cash Ratio	0.10	0.15	0.34	0.33

Efficiency Ratios	Q2 06-30-2018	Q1 03-31-2018	Q3 09-30-2017	Q2 06-30-2017
Accounts Payable to Sales Ratio	0.41	0.34	0.22	0.49
Sales to Working Capital Ratio	0.67	0.50	5.32	2.16
Sales To Inventory (%)	2,560.97	2,269.48	3,993.56	1,354.41
Assets/Sales	673.22	664.77	308.31	716.52
ROCE (%)	2.19	1.89	(1.84)	1.74

Profitability Ratios	Q2 06-30-2018	Q1 03-31-2018	Q3 09-30-2017	Q2 06-30-2017
Return On Net Worth (%)	6.25	3.90	(4.48)	2.50
Return on Assets (%)	1.38	0.94	(1.13)	0.66
Return on Sales (%)	11.10	10.59	(4.83)	10.67
Gross Profit Margin (%)	28.33	28.56	22.78	29.81
Operating Margin (%)	15.18	14.41	(3.13)	14.49
Pre-Tax Profit Margin (%)	11.10	10.59	(4.83)	10.67

Profit Margin (%)	9.26	6.27	(3.48)	4.70
Pre-Tax Return on Equity (%)	7.49	6.59	(6.22)	5.67
After Tax Return on Equity (%)	6.25	3.90	(4.48)	2.50
Operating Income to Interest Ratio	-	-	-	-

Leverage Ratios	Q2 06-30-2018	Q1 03-31-2018	Q3 09-30-2017	Q2 06-30-2017
EBITDA to EBIT Ratio	1.46	1.47	0.32	1.69
Debt to Income Ratio	52.79	74.58	(61.55)	104.31
Debt to Equity Ratio	3.30	2.91	2.76	2.61
Equity Ratio (%)	22.02	24.18	25.16	26.29
Interest Coverage Ratio	-	-	-	-
Interest Coverage to EBITDA Ratio	-	-	-	-

This information may not be reproduced in whole or in part by any means of reproduction.